Trial record 1 of 1 for:
NCT01969578
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01969578 |
|
Recruitment Status :
Recruiting
First Posted : October 25, 2013
Last Update Posted : July 31, 2020
|
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers. The identification of a target, the androgen receptor, in SG tumors has allowed for new treatment strategies options for this rare group of diseases. As a matter of fact, strong positivity for androgen expression has been found in salivary duct carcinoma and adenocarcinomas. The purpose of this study is therefore to evaluate the efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic AR expressing SGCs.
The study will include two cohorts of patients: Cohort A, which comprises chemo-naïve patients, and Cohort B, which comprises pretreated patients.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Salivary Gland Cancer | Drug: bicalutamide + triptorelin Drug: Cisplatin + Doxorubicin Drug: Carboplatin + Paclitaxel | Phase 2 |
Patients in Cohort A will be randomized 1:1 at the study entry to receive ADT (triptorelin + bicalutamide 50 mg) or standard chemotherapy. Patients of Cohort A randomized to the control arm (chemotherapy arm) will be given the option to enter Cohort B at the time of disease progression. As long as Cohort A is open to recruitment, patients who will be treated by chemotherapy will be simultaneously enrolled in Cohort B. Accrual in Cohort B will be stopped when recruitment of 76 eligible patients in Cohort A is reached.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 152 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs) |
| Study Start Date : | February 2015 |
| Estimated Primary Completion Date : | June 2022 |
| Estimated Study Completion Date : | June 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Spinal and bulbar muscular atrophy
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Chemotherapy
Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy |
Drug: Cisplatin + Doxorubicin Drug: Carboplatin + Paclitaxel |
|
Experimental: Androgen Deprivation Therapy (ADT)
ADT = bicalutamide + triptorelin Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized. |
Drug: bicalutamide + triptorelin |
Primary Outcome Measures :
- Progression Free Survival (PFS) [ Time Frame: 37 months after First Patient In ]PFS is a primary outcome for cohort A
- Response rate (RR) [ Time Frame: 37 months after First Patient In ]RR is a primary outcome for cohort B
Secondary Outcome Measures :
- Response Rate (RR) [ Time Frame: 37 months after First Patient In ]RR is a secondary outcome for cohort A
- Progression Free Survival (PFS) [ Time Frame: 37 months after First Patient In ]PFS is a secondary outcome for cohort B
Other Outcome Measures:
- Overall Survival (OS) [ Time Frame: 37 months after First Patient In ]
- Adverse Events according to CTCAE v4.0 [ Time Frame: 37 months after First Patient In ]adverse events will be recorded using International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, the investigator will assess whether those events are drug related (reasonable possibility, no reasonable possibility) and this assessment will be recorded in the database for all adverse events
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically proven diagnosis of recurrent and/or metastatic salivary duct cancer; adenocarcinoma, NOS; and AR expression in at least 70% of nuclei of neoplastic cells based on central review
- Sufficient tissue must be available either historically or a biopsy must be done as a part of this study and sent to central review for patients enrolled in both cohorts
- Presence of at least one uni-dimensional measurable lesion by CT-scan or MRI according to RECIST criteria version 1.1 (target lesion).
- Patients older than 18 years old;
- Performance Status ECOG 0-1;
- Adequate bone marrow function:
- WBC ≥ 3.5/10exp9L
- absolute neutrophil count ≥ 1,5x10exp9/L
- hemoglobin > 9 g/dL
- platelet count ≥ 100x10exp9/L
- Adequate liver function:
- AST < 2.5 times upper limit of normal
- ALT < 2.5 times upper limit of normal
- bilirubin < 1.5 times upper limit of normal
- the concomitant evidence of AST < 2.5 times upper limit of normal, ALT < 2.5 times upper limit of normal and bilirubin > 1.5 times upper limit of normal is not allowed
- Adequate renal function:
- serum creatinine level (≤ 1.3 mg/dL)
- calculated creatinine clearance ≥ 60 mL/min based on the standard Cockcroft and Gault formula
- Adequate cardiac function as demonstrated by a clinically normal 12 lead ECG; additionally for patients who will receive Cisplatin and Doxorubicin adequate cardiac function should be demonstrated by a left ventricular ejection fraction (LVEF) ≥ 50% (within 2 weeks prior to treatment start)
Exclusion Criteria:
- Actively bleeding tumor if the patient is intended to be treated with carboplatin
- Patients with bone disease or brain disease as the sole disease site; brain metastases are allowed in case of systemic disease, but must have been treated at least 4 weeks before enrollment and must be stable after that;
- recent history of congestive heart failure, unstable angina within the past 3 months, cardiac arrhythmia, myocardial infarction, congenital long QTc prolongation, stroke, TIA within the past 6 months;
- previous cardiac toxicity induced by another anthracycline or previous exposure to maximum cumulative dose of another anthracycline if the patient is intended to be treated with doxorubicin
- history of allergic reactions attributed to compounds of similar chemical or biological composition to cis/carboplatin, paclitaxel, doxorubicin, bicalutamide or triptorelin;
- concomitant medications with terfenadine, astemizole, cisaprid
- use of phenytoin
- Patients who received vaccine for yellow fever
- active second malignancy during the last five years except non melanomatous skin cancer or carcinoma in situ of the cervix;
- positive serum pregnancy test within 1 week prior to the first dose of study treatment for Women of child bearing potential (WOCBP);
- no adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment for patients of childbearing / reproductive potential.
- psychological, familiar, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
- written informed consent not given according to ICH/GCP, and national/local regulations, before patient registration
- participation in another interventional clinical trial in the preceding 4 weeks prior to randomization
- for cohort A patients: previous chemotherapy for recurrent/metastatic disease (previous chemotherapy given concomitantly with RT in the past is allowed, including cisplatin but it should be completed at least 6 months before enrollment).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01969578
Contacts
| Contact: EORTC HQ | +32 2 774 1611 | eortc@eortc.org |
Locations
Show 26 study locations
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Investigators
| Principal Investigator: | Lisa Licitra | Fondazione IRCCS ISTITUTO NAZIONALE TUMORI | |
| Study Chair: | Kevin Harrington | The Royal Marsden |
| Responsible Party: | European Organisation for Research and Treatment of Cancer - EORTC |
| ClinicalTrials.gov Identifier: | NCT01969578 |
| Other Study ID Numbers: |
EORTC-1206 2013-000314-38 ( EudraCT Number ) |
| First Posted: | October 25, 2013 Key Record Dates |
| Last Update Posted: | July 31, 2020 |
| Last Verified: | July 2020 |
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
|
salivary duct cancer adenocarcinoma, NOS androgen deprivation androgen receptor |
Additional relevant MeSH terms:
|
Salivary Gland Neoplasms Mouth Neoplasms Head and Neck Neoplasms Neoplasms by Site Neoplasms Mouth Diseases Stomatognathic Diseases Salivary Gland Diseases Paclitaxel Carboplatin Doxorubicin Bicalutamide Triptorelin Pamoate Antineoplastic Agents, Phytogenic Antineoplastic Agents |
Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Androgen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Luteolytic Agents Contraceptive Agents, Female Contraceptive Agents |